Brief: Argenx Announces FDA Approval Of Vyvgart Hytrulo For Chronic Inflammatory Demyelinating Polyneuropathy
21/06/2024 23:18
argenx SE ARGX.BR :
* ARGENX ANNOUNCES FDA APPROVAL OF VYVGART HYTRULO FOR
CHRONIC
INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Source text for Eikon: ID:nGNX3Nyd8h
Further company coverage: ARGX.BR
Recent news on argenx SE
See all newsArgenx falls after Vyvgart trial update on myositis drug, brokers remain positive
Brief: ArgenX Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit In Myositis And Sjogren’S Disease
Brief: argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Brief: Argenx Q1 Total Operating Income USD 1.313 Bln
Netherlands' Argenx Q1 net sales rise 63%, profit more than doubles